1. Home
  2. Analysis
  3. Carvedilol
  4. Farydak

Carvedilol and Farydak drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Carvedilol (carvedilol) and Farydak (panobinostat lactate). Common drug interactions include death among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Carvedilol and Farydak. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Carvedilol?

Carvedilol has active ingredients of carvedilol. It is often used in high blood pressure. eHealthMe is studying from 112,649 Carvedilol users. Check the latest studies of Carvedilol.

What is Farydak?

Farydak has active ingredients of panobinostat lactate. eHealthMe is studying from 1,513 Farydak users. Check the latest studies of Farydak.

On Jul, 05, 2026

11 people who take Carvedilol and Farydak together, and have interactions are studied.

Carvedilol and Farydak drug interactions.

What are the common drug interactions of Carvedilol and Farydak, by gender? *:

female:

  1. Death
  2. Plasma cell myeloma (cancer that begins in plasma cells)
  3. Renal failure (kidney dysfunction)
  4. Diarrhoea
  5. Disease progression
  6. Cardiac failure

male:

  1. Death
  2. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
  3. Drug ineffective
  4. Full blood count decreased
  5. Haemoglobin decreased
  6. Lung disorder (lung disease)
  7. Nausea (feeling of having an urge to vomit)
  8. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  9. Respiratory disorder (respiratory disease)

What are the common drug interactions of Carvedilol and Farydak, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Cardiac failure
  2. Plasma cell myeloma (cancer that begins in plasma cells)
  3. Renal failure (kidney dysfunction)
  4. Death
  5. Disease progression

What are the existing conditions these people have? *

  1. Multiple Myeloma (cancer of the plasma cells): 11 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Carvedilol and Farydak?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Carvedilol and Farydak:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Carvedilol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Farydak:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Carvedilol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Farydak and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on carvedilol and panobinostat lactate (the active ingredients of Carvedilol and Farydak, respectively), and Carvedilol and Farydak (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.